Pyng Medical Corp.
TSX VENTURE : PYT

Pyng Medical Corp.

November 25, 2008 09:00 ET

Pyng Medical Appoints Nadine Gaston as Vice President, US Sales

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 25, 2008) - Pyng Medical Corp. (TSX VENTURE:PYT) today announced the appointment of Nadine Gaston to serve as the Company's newly created Vice President, US Sales. Working collaboratively with the Vice President, International Sales and the Management Team, Ms. Gaston will lead the development and implementation of a strategic sales plan focused exclusively on growing market share in the US civilian and military markets.

Ms. Gaston brings more than fifteen years of industry experience as an award-winning sales and marketing executive. Nadine joins Pyng Medical from Physio-Control Inc., a division of Medtronic Inc. based in Redmond, WA, where she excelled in a variety of increasingly senior positions during the past 10 years, including Sales Manager - West, Director of Market Development, and Senior Marketing Manager. Nadine earned a B.A. in Marketing from Seattle Pacific University and graduated from the Medtronic Marketing Executive MBA Program, Wharton Business School.

"I am pleased to facilitate the rapid market adoption of Pyng Medical's portfolio of market-leading products in the US," stated Ms. Gaston. "Given the proven performance of the Company's flagship FAST1™ Intraosseous Infusion System and several recently acquired trauma products, Pyng has a tremendous opportunity to improve public health and safety while increasing market share in the trauma and resuscitation space."

"Nadine has an impressive track record as a top performing sales leader experienced in successfully launching national US sales initiatives into the large EMS and hospital markets," stated David Christie, President and CEO. "As we prepare to commercially launch our CRIC™ Chricothyrotomy System mid-year, I look forward to supporting her efforts as we leverage our distribution strength and compete on superior performance to meet our aggressive sales and revenue targets for 2009 and beyond."

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Creators of the FAST1® Intraosseous Infusion System, Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide. Pyng has received the exclusive 2008 Medical Device Company of the Year Award from Life Sciences British Columbia for its sustained achievements in commercializing the Company's proprietary FAST1®, the only medical device able to provide rapid sternal access for administering drugs and fluids to the heart in seconds. The Company was also selected in the "2007 TSX Venture 50" Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Pyng Medical Corp.
    David Chrsitie
    (604) 303-7964
    Website: www.pyng.com